Disease or Syndrome
FDA Approves Cytokinetics’ Myqorzo for Obstructive Hypertrophic Cardiomyopathy, Positioning It Against BMS’s Camzyos
FDA approval; Cytokinetics; Myqorzo; aficamten; obstructive hypertrophic cardiomyopathy; Bristol Myers Squibb; Camzyos
BioMarin Announces $4.8 Billion Acquisition of Amicus Therapeutics for Rare Disease Portfolio Expansion
BioMarin; Amicus Therapeutics; acquisition; $4.8B; Galafold; Pombiliti; Opfolda; rare diseases
Bayer’s Finerenone Approved in Japan for Chronic Heart Failure Treatment
Finerenone; Kerendia; Japan approval; chronic heart failure; HFmrEF; HFpEF; Bayer; FINEARTS-HF
FDA places partial clinical hold on Merck and Daiichi Sankyo’s I-DXd lung cancer trial after interstitial lung disease deaths
FDA partial clinical hold; ifinatamab deruxtecan; I-DXd; IDeate-Lung02; Merck; Daiichi Sankyo; small cell lung cancer; interstitial lung disease; grade 5 ILD; antibody-drug conjugate; clinical trial deaths
Recent Biotech News: Altimmune’s Pemvidutide Advances in MASH, Emerging China Obesity Players, and Ipsen Phase 2 Setback
Altimmune; pemvidutide; MASH; Phase 2b; IMPACT trial; FDA; China obesity; Ipsen; Phase 2 fail
Insmed Delivers Rare Disappointment as Brinsupri Flops in Mid-Stage Rhinosinusitis Study
Insmed; Brensocatib; Brinsupri; DPP1 inhibitor; chronic rhinosinusitis without nasal polyps; mid-stage trial; Phase 2b; nasal inflammation; trial failure; biotech stocks; INS1148 acquisition
Ipsen’s Fidrisertib Fails Primary Endpoint in Pivotal Phase II FALKON Trial for Rare Bone Disease FOP
Ipsen; fidrisertib; FALKON trial; FOP; Phase II failure; heterotopic ossification
GSK strikes RNA-based neuro and kidney disease collaboration with CAMP4 Therapeutics
GSK; CAMP4 Therapeutics; RNA therapeutics; regulatory RNA; antisense oligonucleotides; ASO; RAP Platform; neurodegenerative diseases; kidney disease; renal disease; gene upregulation; biotech collaboration; licensing deal; milestone payments; tiered royalties
Lilly seeks rapid FDA approval for oral GLP-1 orforglipron after positive obesity “switching” study
Eli Lilly; orforglipron; oral GLP-1; FDA approval; national priority review voucher; ATTAIN-MAINTAIN trial; obesity treatment; weight maintenance; Zepbound; Wegovy; injectable incretins; Phase 3 trial
No public results for “Take the Biopharma Sentiment Index” Q1 2026 yet
Biopharma Sentiment Index; Q1 2026; biopharma executives; life sciences sentiment; 2026 outlook; M&A activity; AI in biopharma; geopolitical risk; survey data